BCAL Diagnostics has locked in an additional $4.9 million under its existing convertible note facility alongside a $1.4 million R&D tax offset tranche, reinforcing its funding runway into FY2027 for early cancer detection test development.
- Additional $4.9 million funding under $10 million convertible note facility
- First $1.4 million tranche of FY2026 R&D tax offset expected end of June
- Funds to support development and commercialisation of blood-based cancer tests
- Portfolio includes BREASTESTplus, Avantect Pancreatic and Ovarian tests
- Funding underpins BCAL’s FY2027 commercialisation and R&D activities
Convertible Note Facility Extended with $4.9 Million
BCAL Diagnostics (ASX:BDX) has secured firm commitments for an additional $4.9 million under its existing $10 million convertible note facility, extending its funding runway for the 2027 financial year. The company can draw down these funds as needed, providing flexibility to support ongoing operations and development.
R&D Tax Offset Boosts Non-Dilutive Funding
Adding to this capital, BCAL expects to receive the first tranche of its FY2026 Research & Development tax offset claim, amounting to approximately $1.4 million, around 30 June 2026. This payment represents just over half of the total expected $2.5 million R&D tax offset, with the remainder anticipated in October. Such offsets remain a key non-dilutive financing source for the company’s innovation efforts.
Backing Commercialisation of Blood-Based Cancer Tests
The secured funding will underpin BCAL’s strategy to advance and commercialise its blood-based early cancer detection portfolio. This includes the flagship BREASTESTplus, designed to improve breast cancer screening especially for women with dense breast tissue, alongside the Avantect® Pancreatic and Ovarian tests and the multi-cancer test currently in development. These products aim to make cancer detection simpler and more accessible.
CEO Highlights Strategic Importance of Funding
Newly appointed CEO Anne-Louise Arnett emphasised the significance of these funding milestones. She noted the convertible note extension and R&D tax offsets as critical enablers for BCAL’s commercialisation push, focusing on expanding access to blood-based cancer tests for doctors and patients. This financial backing arrives amid BCAL’s efforts to integrate its tests into GP software platforms and launch telehealth services, signalling a broader go-to-market acceleration.
Positioning for Growth in Early Cancer Detection
BCAL’s portfolio and partnerships, including its exclusive license with US-based ClearNote Health for Avantect tests in Australia and New Zealand, position it well within the early cancer detection sector. The company’s ability to secure additional funding under existing facilities and leverage government R&D incentives reflects ongoing investor and institutional confidence in its technology and commercial prospects.
Bottom Line?
BCAL’s fresh funding extends its runway through FY2027, setting the stage for critical commercial milestones in blood-based cancer testing.
Questions in the middle?
- How will BCAL prioritise drawdown timing under the convertible note facility?
- What commercial milestones can investors expect in the next 12 months?
- How might upcoming R&D tax offset receipts influence BCAL’s cash flow and investment pace?